Calabadion, el nuevo Reversor Muscular
DOI:
https://doi.org/10.30445/rear.v9i12.602Palabras clave:
GATIV, calabadion, Sugammadex, bloqueantes neuromusculares, reversorResumen
Todavía no comercializado, Calabadion 2; un nuevo reversor de los bloqueantes neuromusculares. Se une al rocuronio con una afinidad 89 veces mayor que el Sugammadex.
Citas
1. Haerter F, Eikermann M. Reversing neuromuscular blockade: inhibitors of the acetylcholinesterase versus the encapsulating agents sugammadex and calabadion. Expert Opin Pharmacother. 2016;17(6):819-33.
2. Macartney DH. Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents. Future Med Chem. 2013 Nov;5(17):2075-89.
3. Diaz-Gil D, Haerter F, Falcinelli S, Ganapati S, Hettiarachchi GK, Simons JC, Zhang B, Grabitz SD, Moreno Duarte I et al. A Novel Strategy to Reverse General Anesthesia by Scavenging with the Acyclic Cucurbit[n]uril-type Molecular Container Calabadion 2. Anesthesiology. 2016 Aug;125(2):333-45.
4. Ganapati S, Zavalij PY, Eikermann M, Isaacs L. In Vitro selectivity of an acyclic cucurbit[n]uril molecular container towards neuromuscular blocking agents relative to commonly used drugs. Org Biomol Chem. 2016 Jan 28;14(4):1277-87
5. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, Zaremba S, Ayata C, Zhang B, Ma D, Isaacs L, Eikermann M. Calabadion: A new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology. 2013 Aug;119(2):317-25.
2. Macartney DH. Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents. Future Med Chem. 2013 Nov;5(17):2075-89.
3. Diaz-Gil D, Haerter F, Falcinelli S, Ganapati S, Hettiarachchi GK, Simons JC, Zhang B, Grabitz SD, Moreno Duarte I et al. A Novel Strategy to Reverse General Anesthesia by Scavenging with the Acyclic Cucurbit[n]uril-type Molecular Container Calabadion 2. Anesthesiology. 2016 Aug;125(2):333-45.
4. Ganapati S, Zavalij PY, Eikermann M, Isaacs L. In Vitro selectivity of an acyclic cucurbit[n]uril molecular container towards neuromuscular blocking agents relative to commonly used drugs. Org Biomol Chem. 2016 Jan 28;14(4):1277-87
5. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, Zaremba S, Ayata C, Zhang B, Ma D, Isaacs L, Eikermann M. Calabadion: A new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology. 2013 Aug;119(2):317-25.
Publicado
2017-05-22
Cómo citar
Blasco Mariño, R., & Abad Torrent, A. (2017). Calabadion, el nuevo Reversor Muscular. Revista Electrónica AnestesiaR, 9(12), 3. https://doi.org/10.30445/rear.v9i12.602
Número
Sección
Artículos de revisión
Revista Electrónica AnestesiaR by 